UK approves GSK antibody COVID-19 drug

Thursday, 02. December 2021 08:53

The United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) unveiled on Thursday it has approved the monoclonal antibody drug sotrovimab, developed by GlaxoSmithKline plc, "for people with mild to moderate COVID-19 who are at high risk of developing severe disease."

Earlier in the day, the pharmaceutical company unveiled that its treatment is likely to be effective against the coronavirus' Omicron variant.

MHRA has previously given a green light to Ronapreve, a monoclonal antibody COVID drug developed by Regeneron Pharmaceuticals, Inc.

Related Links: GlaxoSmithKline PLC
Baha Breaking News (BBN) / BU